Sanofi
A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi (SNY) and Johnson & Johnson’s (This content is for paid subscribers.
Sanofi Updates on Extraintestinal Pathogenic E. coli Vaccine Phase 3 Clinical Study
Today’s Highlights February 13, 2025
Today’s Highlights
February 13, 2025
-
February 12, 2025 0